News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 37–72
- Matches
- 210
- Sources here
- 17
- Companies here
- 8
Active search
210 matching headlines
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Helmerich & Payne (HP) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
For the quarter ended June 2026, Helmerich & Payne (HP) reported revenue of $1.03 billion, down 0.6% over the same period last year. EPS came in at -$0.11, compared to $0.22 in the year-ago quarter. The reported revenue represents a surprise of +4.7% over …
Helmerich & Payne (NYSE:HP) Price Target Raised to $44.00
Susquehanna has raised its price target for Helmerich & Payne (NYSE:HP) to $44.00 from $40.00, maintaining a "positive" rating and implying an 18.7% upside. Despite this, the stock holds an overall "Hold" rating from analysts, with an average target price of $40.20. The company …
RELMADA THERAPEUTICS, INC. 2Q 2026: Net loss $12.9M, EPS $(0.11) — 10-Q Summary
RELMADA THERAPEUTICS, INC. reported a net loss of $12.9 million and a diluted loss per share of $0.11 for the second quarter of 2026. This widened loss compared to the previous year is attributed to increased R&D and manufacturing spending to advance its pipeline. …
Press Release: Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Relmada Therapeutics announced its second quarter 2026 financial results and provided a business update. The report details the company's financial performance during this period and outlines key developments in its business operations. This release offers stakeholders insight into Relmada's recent progress and future outlook.
Relmada Therapeutics Inc (RLMD) (Q2 2026) Earnings Call Highlights: Strong Phase 2 Data and FDA ...
Relmada Therapeutics Inc (RLMD) reported strong Phase 2 data for NDVO1 and has FDA alignment on registrational pathways. Despite a strong balance sheet and plans for IND filings by the end of 2026, the company faces delays in NDVO1 IND filing due to manufacturing …
Relmada Q2 2026 earnings: R&D spending rises ahead of planned IND filings
Relmada Therapeutics reported a wider net loss of $12.9 million in Q2 2026, despite a narrowed GAAP loss per share, driven by a nearly threefold increase in R&D expenses to $8.4 million. The company is prioritizing manufacturing and regulatory preparations for its NDV-01 and …
Earnings call transcript: Relmada posts Q2 2026 EPS beat as shares slip
Relmada Therapeutics reported a narrower-than-expected Q2 2026 loss of $0.11 per share, beating analyst estimates, but its shares fell due to investor focus on drug development timelines and higher research spending. The company's lead drug, NDV-01 for bladder cancer, and sepranolone for Prader-Willi syndrome, …
Elmet Group (ELMT) Insider Trading Activity 2026
This article details the insider trading activity for Elmet Group (ELMT) in 2026, showing that two insiders, Kathie Merrill Leonard and Kimberly Monzeglio Anania, purchased a total of 12,000 shares for $168,000. It provides specific transaction dates, share amounts, and average prices for these …
Relmada Therapeutics (Nasdaq: RLMD) details Q2 2026 loss and NDV-01 Phase 3 path
Relmada Therapeutics reported a net loss of $12.9 million for Q2 2026, alongside a business update on its oncology and CNS pipeline. The company is advancing its lead candidate, NDV-01, for non-muscle invasive bladder cancer towards a Phase 3 registrational program, with an IND …
Form 8K Relmada Therapeutics Inc For: 6 August By Investing.com
This article reports on the filing of a Form 8K by Relmada Therapeutics Inc. on August 6th. The content is brief and serves primarily as an announcement of this regulatory filing, likely containing important company updates.
Helmerich & Payne 2026: Revenue $986.88M, EPS $0.74— 10-Q Summary
Helmerich & Payne reported strong results for the quarter ended 2026, with revenue of $986.88M and diluted EPS of $0.74, a significant improvement from the prior year, largely due to contributions from international and offshore segments following a major acquisition. The company's consolidated nine-month …
(GEGGL) and the Role of Price-Sensitive Allocations
This article provides an AI-generated analysis for Great Elm Group Inc. 7.25% Notes Due 2027 (NASDAQ: GEGGL), indicating a neutral sentiment with a mid-channel oscillation pattern. It highlights an exceptional 7.1:1 risk-reward setup targeting a 2.0% gain. The analysis also outlines three distinct institutional …
A new drilling rig is expected in Australia's Beetaloo Basin in Q2 2027
Formentera Partners, Daly Waters Energy, and INPEX have contracted a Helmerich & Payne FlexRig for operations in Australia's Beetaloo Basin, expected to arrive in Q2 2027. This marks H&P's second rig in the Beetaloo Basin and third in Australia, securing critical drilling capacity through …
Formentera Partners Scales Up U.S. Shale Technology in Australia
Additional Helmerich & Payne FlexRig® supports growing development in the Northern Territory's Beetaloo Basin AUSTIN, Texas, August 06, 2026--(BUSINESS WIRE)--Formentera Partners, its Australian operating company, Daly Waters Energy (DWE), and INPEX Pty Ltd (INPEX) today announced that, together with Helmerich & Payne (NYSE: HP), …
Great Elm Group declares $0.25 dividend
* Great Elm Group (GEG [https://seekingalpha.com/symbol/GEG]) declares $0.25/share quarterly dividend [https://seekingalpha.com/pr/20608651-great-elm-capital-corp-announces-second-quarter-2026-financial-results]. * Forward yield [https://seekingalpha.com/symbol/GEG/dividends/yield?source=news_bullet] 46.3% * Payable Sept. 30; for shareholders of record Sept. 15; ex-div Sept. 15. * See GEG Dividend Scorecard, Yield Chart, & Dividend Growth. [https://seekingalpha.com/symbol/GEG/dividends?source=news_bullet] MORE ON GREAT ELM …
Press Release: Helmerich & Payne, Inc. Announces Fiscal Third Quarter Results
Helmerich & Payne, Inc. announced its fiscal third quarter results. The company reported its financial performance for the period, detailing key metrics and operational highlights. This release provides stakeholders with an update on the company's financial health and strategic direction.
Helmerich & Payne (HP) Reports Q3 Loss, Beats Revenue Estimates
Helmerich & Payne (HP) reported a Q3 loss of $0.11 per share, which was in line with the Zacks Consensus Estimate, but marked a significant drop from the $0.22 earnings per share a year ago. The company, an oil and gas well-drilling contractor, exceeded …
Earnings Flash (HP) Helmerich & Payne, Inc. Posts Q3 Adjusted Loss $0.11 per Share, vs. FactSet Est for EPS of $0.09
Helmerich & Payne, Inc. (HP) reported an adjusted loss of $0.11 per share for the third quarter, which contrasts with FactSet's estimated earnings per share of $0.09. This financial update indicates that the company's Q3 performance fell short of analyst expectations. The announcement was …
Helmerich & Payne (NYSE:HP) Reports Upbeat Q2 CY2026
Helmerich & Payne (NYSE:HP) Reports Upbeat Q2 CY2026 Land drilling contractor Helmerich & Payne (NYSE:HP) reported Q2 CY2026 results exceeding the market's revenue expectations , but sales were flat year on year at $1.03 billion. Its GAAP profit of $0.74 per share was significantly …
Earnings Flash (HP) Helmerich & Payne, Inc. Reports Q3 Revenue $1.03B, vs. FactSet Est of $987.7M
Helmerich & Payne, Inc. (HP) reported its Q3 revenue at $1.03 billion, exceeding FactSet's estimate of $987.7 million. The company's stock shows a positive performance with a 5-day change of +11.39% and a year-to-date change of +29.25%. This financial update comes amidst various company …
Great Elm Group (NASDAQ:GEG) Stock Price Down 8.9% - What's Next?
Great Elm Group (NASDAQ:GEG) saw its stock price fall 8.9% to $2.15 on Tuesday, with trading volume significantly higher than average. Analysts maintain a "Sell" rating on the stock, citing a recent downgrade from Weiss Ratings. The company reported a substantial quarterly loss of …
Helmerich Payne earnings on deck as drilling market recovers
Helmerich & Payne Inc. is set to report its fiscal fourth-quarter earnings, with analysts anticipating a significant turnaround from the previous quarter's loss. Investors will be looking for signs that the U.S. rig market has bottomed out and that a multi-year recovery is underway, …
Helmerich and Payne Inc expected to post earnings of 13 cents a share - Earnings Preview
Helmerich and Payne Inc is anticipated to report earnings of 13 cents per share. This information is based on an earnings preview from Refinitiv, which is available on TradingView News.
Elmet Group Co. (NASDAQ:ELMT) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Analysts have issued a "Moderate Buy" consensus recommendation for Elmet Group Co. (NASDAQ:ELMT), with an average 12-month price target of $20.50, significantly higher than its opening price of $14.36. The company recently surpassed quarterly earnings expectations, reporting $0.23 EPS against an estimated $0.18 loss …